Transglutaminase 2 Inhibitor, ZDON, A cell-permeable, peptide-based, irreversible inhibitor of transglutaminase 2 (TG2; IC₅₀ = 150 nM for recombinant TG2). Reacts with the active site cysteine of TG2.
A cell-permeable, peptide-based (Z- QVPL) irreversible inhibitor of transglutaminase 2 (TG2) (IC50 = 150 nM for recombinant TG2) that acts by reacting with the active site cysteine of TG2. Exhibits far less potency against TG1 and TG3. Shown to significantly increase PGC-1a and cytochrome c mRNA levels in Q7 and Q111 cells (~50 mM). Also shown to enhance cytochrome c promoter activity by 250% in Q111 cells. Exhibits protective effect in cells exposed to 3-nitropropionic acid and NMDA, however, it does not directly affect mitochondrial bioenergetics.
警告
Toxicity: Standard Handling (A)
再構成
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
その他情報
McConoughey, S. J., et al. 2010. EMBO Mol. Medicine.2, 349.
法的情報
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Transglutaminase 2 (TG2), also known as tissue transglutaminase, is a calcium-dependent enzyme that has a variety of intracellular and extracellular substrates. TG2 not only increases in osteoarthritis (OA) tissue but also affects the progression of OA. However, it is still
International journal of molecular sciences, 24(15) (2023-08-12)
Transglutaminase 2 (TG2) is a multifunctional protein widely distributed in various tissues and involved in many physiological and pathological processes. However, its actual role in biological processes is often controversial as TG2 shows different effects in these processes depending on
The major barrier to a HIV-1 cure is the persistence of latent genomes despite treatment with antiretrovirals. To investigate host factors which promote HIV-1 latency, we conducted a genome-wide functional knockout screen using CRISPR-Cas9 in a HIV-1 latency cell line